109 related articles for article (PubMed ID: 20825973)
1. Matrix metalloproteinase 9 is associated with Gleason score in prostate cancer but not with prognosis.
Trudel D; Fradet Y; Meyer F; Têtu B
Hum Pathol; 2010 Dec; 41(12):1694-701. PubMed ID: 20825973
[TBL] [Abstract][Full Text] [Related]
2. Membrane-type-1 matrix metalloproteinase, matrix metalloproteinase 2, and tissue inhibitor of matrix proteinase 2 in prostate cancer: identification of patients with poor prognosis by immunohistochemistry.
Trudel D; Fradet Y; Meyer F; Harel F; Têtu B
Hum Pathol; 2008 May; 39(5):731-9. PubMed ID: 18329693
[TBL] [Abstract][Full Text] [Related]
3. Significance of MMP-2 expression in prostate cancer: an immunohistochemical study.
Trudel D; Fradet Y; Meyer F; Harel F; Têtu B
Cancer Res; 2003 Dec; 63(23):8511-5. PubMed ID: 14679018
[TBL] [Abstract][Full Text] [Related]
4. Expression of matrix metalloproteinase-2 and -9 and their inhibitors, tissue inhibitor of metalloproteinase-1 and -2, in primary cultures of human prostatic stromal and epithelial cells.
Wilson MJ; Sellers RG; Wiehr C; Melamud O; Pei D; Peehl DM
J Cell Physiol; 2002 May; 191(2):208-16. PubMed ID: 12064464
[TBL] [Abstract][Full Text] [Related]
5. Differential expression of matrix metalloproteinase (MMP)-2, MMP-9, and membrane type 1-MMP in hepatocellular and pancreatic adenocarcinoma: implications for tumor progression and clinical prognosis.
Määttä M; Soini Y; Liakka A; Autio-Harmainen H
Clin Cancer Res; 2000 Jul; 6(7):2726-34. PubMed ID: 10914717
[TBL] [Abstract][Full Text] [Related]
6. Reactive stroma as a predictor of biochemical-free recurrence in prostate cancer.
Ayala G; Tuxhorn JA; Wheeler TM; Frolov A; Scardino PT; Ohori M; Wheeler M; Spitler J; Rowley DR
Clin Cancer Res; 2003 Oct; 9(13):4792-801. PubMed ID: 14581350
[TBL] [Abstract][Full Text] [Related]
7. Quantitative immunohistochemical and in situ hybridization analysis of metalloproteinases in prostate cancer.
Cardillo MR; Di Silverio F; Gentile V
Anticancer Res; 2006; 26(2A):973-82. PubMed ID: 16619495
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of epithelial macrophage colony-stimulating factor (CSF-1) and CSF-1 receptor: a poor prognostic factor in epithelial ovarian cancer, contrasted with a protective effect of stromal CSF-1.
Chambers SK; Kacinski BM; Ivins CM; Carcangiu ML
Clin Cancer Res; 1997 Jun; 3(6):999-1007. PubMed ID: 9815777
[TBL] [Abstract][Full Text] [Related]
9. Type IV collagenase (matrix metalloproteinase-2 and -9) in prostate cancer.
Zhang L; Shi J; Feng J; Klocker H; Lee C; Zhang J
Prostate Cancer Prostatic Dis; 2004; 7(4):327-32. PubMed ID: 15356679
[TBL] [Abstract][Full Text] [Related]
10. Androgen receptor expression in prostate cancer lymph node metastases is predictive of outcome after surgery.
Sweat SD; Pacelli A; Bergstralh EJ; Slezak JM; Cheng L; Bostwick DG
J Urol; 1999 Apr; 161(4):1233-7. PubMed ID: 10081876
[TBL] [Abstract][Full Text] [Related]
11. Expression of matrix metalloproteinase (MMP)-2 and MMP-9 in breast cancer with a special reference to activator protein-2, HER2, and prognosis.
Pellikainen JM; Ropponen KM; Kataja VV; Kellokoski JK; Eskelinen MJ; Kosma VM
Clin Cancer Res; 2004 Nov; 10(22):7621-8. PubMed ID: 15569994
[TBL] [Abstract][Full Text] [Related]
12. Inducible nitric oxide synthase (iNOS) expression and its prognostic value in prostate cancer.
Aaltoma SH; Lipponen PK; Kosma VM
Anticancer Res; 2001; 21(4B):3101-6. PubMed ID: 11712818
[TBL] [Abstract][Full Text] [Related]
13. Prognostic factors for survival of patients with pathological Gleason score 7 prostate cancer: differences in outcome between primary Gleason grades 3 and 4.
Lau WK; Blute ML; Bostwick DG; Weaver AL; Sebo TJ; Zincke H
J Urol; 2001 Nov; 166(5):1692-7. PubMed ID: 11586204
[TBL] [Abstract][Full Text] [Related]
14. Caveolin-1 expression is a predictor of recurrence-free survival in pT2N0 prostate carcinoma diagnosed in Japanese patients.
Satoh T; Yang G; Egawa S; Addai J; Frolov A; Kuwao S; Timme TL; Baba S; Thompson TC
Cancer; 2003 Mar; 97(5):1225-33. PubMed ID: 12599229
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of stromal metalloproteinase-2 in ovarian adenocarcinoma and its relation to carcinoma progression.
Torng PL; Mao TL; Chan WY; Huang SC; Lin CT
Gynecol Oncol; 2004 Feb; 92(2):559-67. PubMed ID: 14766248
[TBL] [Abstract][Full Text] [Related]
16. Androgen receptor levels in prostate cancer epithelial and peritumoral stromal cells identify non-organ confined disease.
Ricciardelli C; Choong CS; Buchanan G; Vivekanandan S; Neufing P; Stahl J; Marshall VR; Horsfall DJ; Tilley WD
Prostate; 2005 Apr; 63(1):19-28. PubMed ID: 15378523
[TBL] [Abstract][Full Text] [Related]
17. Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma.
Cheng L; Jones TD; Lin H; Eble JN; Zeng G; Carr MD; Koch MO
J Urol; 2005 Dec; 174(6):2181-5. PubMed ID: 16280760
[TBL] [Abstract][Full Text] [Related]
18. Expression of sialylated MUC1 in prostate cancer: relationship to clinical stage and prognosis.
Arai T; Fujita K; Fujime M; Irimura T
Int J Urol; 2005 Jul; 12(7):654-61. PubMed ID: 16045558
[TBL] [Abstract][Full Text] [Related]
19. Pretreatment serum level of HER2/nue as a prognostic factor in metastatic prostate cancer patients about to undergo endocrine therapy.
Okegawa T; Kinjo M; Nutahara K; Higashihara E
Int J Urol; 2006 Sep; 13(9):1197-201. PubMed ID: 16984552
[TBL] [Abstract][Full Text] [Related]
20. Ki-67 expression is a prognostic marker of prostate cancer recurrence after radical prostatectomy.
Bettencourt MC; Bauer JJ; Sesterhenn IA; Mostofi FK; McLeod DG; Moul JW
J Urol; 1996 Sep; 156(3):1064-8. PubMed ID: 8709308
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
